MedPulse Medical Technology Co., Ltd.
MedPulse Medical Technology Co., Ltd. (MedPulse Medical Technology Co., Ltd., referred to as "MedPulse Medical"), was established in January 2018. It has always been committed to providing customers with comprehensive and high-quality scientific research experimental products and technical services. The company has established long-term and stable cooperative relations with many leading biopharmaceutical companies in China, and its agent product lines are extensive, including but not limited to proteins, nucleic acids, DNA/RNA, molecules, antibodies, cells/cell culture, ELISA kits, laboratory consumables, as well as animal modeling, organoids and gene editing and other technical services. With its professional agency team, rich market experience and high-quality services, the company has quickly emerged in the field of biopharmaceutical agency and established a good reputation and brand image in the industry. The company adheres to the corporate culture of "integrity, professionalism, efficiency and innovation", focuses on the innovation and application of biotechnology, and is committed to providing high-quality biotechnology products and solutions to global customers. The company will work hand in hand with global partners with a more open mind and more pragmatic actions to jointly promote the development of the biotechnology industry and contribute greater strength to human health.
Scale and quality control: Cooperative manufacturers such as Shanghai Yamei, Wuhan Beiyinlai, and Nanjing Senbeijia have R&D centers and production bases of thousands to tens of thousands of square meters. The core team members are all doctors and masters from well-known domestic universities. They have passed the ISO9001 quality management system certification and have many invention patents and utility model patents.
Product and price advantages: Products are benchmarked against international brands and are more cost-effective. The sales service network covers many Southeast Asian countries such as Japan, South Korea, Singapore, Indonesia and Malaysia.
